Mouton Johannes P, Mehta Ushma, Parrish Andy G, Wilson Douglas P K, Stewart Annemie, Njuguna Christine W, Kramer Nicole, Maartens Gary, Blockman Marc, Cohen Karen
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town.
Independent Pharmacovigilance Consultant, Cape Town.
Br J Clin Pharmacol. 2015 Oct;80(4):818-26. doi: 10.1111/bcp.12567. Epub 2015 Jul 6.
Fatal adverse drug reactions (ADRs) are important causes of death, but data from resource-limited settings are scarce. We determined the proportion of deaths in South African medical inpatients attributable to ADRs, and their preventability, stratified by human immunodeficiency virus (HIV) status.
We reviewed the folders of all patients who died over a 30 day period in the medical wards of four hospitals. We identified ADR-related deaths (deaths where an ADR was 'possible', 'probable' or 'certain' using WHO-UMC criteria and where the ADR contributed to death). We determined preventability according to previously published criteria.
ADRs contributed to the death of 2.9% of medical admissions and 56 of 357 deaths (16%) were ADR-related. Tenofovir, rifampicin and co-trimoxazole were the most commonly implicated drugs. 43% of ADRs were considered preventable. The following factors were independently associated with ADR-related death: HIV-infected patients on antiretroviral therapy (adjusted odds ratio (aOR) 4.4, 95% confidence interval (CI) 1.6, 12), exposure to more than seven drugs (aOR 2.5, 95% CI 1.3, 4.8) and increasing comorbidity score (aOR 1.3, 95% CI 1.1, 1.7).
In our setting, where HIV and tuberculosis are highly prevalent, fatal in-hospital ADRs were more common than reported in high income settings. Most deaths were attributed to drugs used in managing HIV and tuberculosis. A large proportion of the ADRs were preventable, highlighting the need to strengthen systems for health care worker training and support.
致命性药物不良反应(ADR)是重要的死亡原因,但资源有限地区的数据稀缺。我们确定了南非内科住院患者中因ADR导致的死亡比例及其可预防性,并按人类免疫缺陷病毒(HIV)感染状况进行分层。
我们查阅了四家医院内科病房30天内所有死亡患者的病历。我们确定了与ADR相关的死亡(根据世界卫生组织药物不良反应因果关系评价体系标准,ADR为“可能”“很可能”或“肯定”且该ADR导致死亡)。我们根据先前公布的标准确定可预防性。
ADR导致2.9%的内科住院患者死亡,357例死亡中有56例(16%)与ADR相关。替诺福韦、利福平和复方新诺明是最常涉及的药物。43%的ADR被认为是可预防的。以下因素与ADR相关死亡独立相关:接受抗逆转录病毒治疗的HIV感染患者(调整比值比(aOR)4.4,95%置信区间(CI)1.6,12)、使用七种以上药物(aOR 2.5,95%CI 1.3,4.8)以及合并症评分增加(aOR 1.3,95%CI 1.1,1.7)。
在我们这个HIV和结核病高度流行的地区,医院内致命性ADR比高收入地区报告的更为常见。大多数死亡归因于用于治疗HIV和结核病的药物。很大一部分ADR是可预防的,这突出表明需要加强医护人员培训和支持体系。